PH
PHI1.F Koninklijke Philips NV
- Market cap
- EUR 26.8B
- P/E
- 66.9x
- P/B
- 2.29x
- ROE
- 6.5%
- Dividend yield
- 1.22%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PHI1.F undervalued?
Graham numberPHI1.F trades 160.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Koninklijke Philips NV fundamental analysis
No fundamental analysis for Koninklijke Philips NV yet.
Koninklijke Philips NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Koninklijke Philips NV
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers …
Full company profileKoninklijke Philips NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Koninklijke Philips NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 24.5B | 17.8B | 18.1B | 19.5B | 19.5B | 17.2B | 17.8B | 18.2B | 18.0B | 17.8B | 16.9B |
| Gross Profit | 10.6B | 8.18B | 8.55B | 8.88B | 8.78B | 7.17B | 7.19B | 7.45B | 7.77B | 8.06B | 7.94B |
| Operating Income | 1.89B | 1.52B | 1.64B | 1.65B | 1.54B | 505M | -171M | -168M | 513M | 1.45B | 1.36B |
| EBITDA | - | 2.67B | 2.78B | 3.13B | 3.18B | 2.02B | 129M | 1.04B | 1.85B | 2.60B | 2.69B |
| Net Income | 1.45B | 1.66B | 1.09B | 1.17B | 1.19B | 3.32B | -1.61B | -466M | -702M | 895M | 749M |
| EPS | - | 1.75 | 1.17 | 1.28 | 1.31 | 3.81 | -1.75 | -0.50 | -0.76 | 0.94 | 0.77 |
| Balance Sheet | |||||||||||
| Total Assets | 32.3B | 25.3B | 26.0B | 27.0B | 27.7B | 31.0B | 30.7B | 29.4B | 29.0B | 26.9B | 28.0B |
| Total Liabilities | 18.8B | 13.3B | 13.9B | 14.4B | 15.8B | 16.5B | 17.4B | 17.3B | 16.9B | 16.0B | 16.4B |
| Shareholders' Equity | 12.6B | 12.0B | 12.1B | 12.6B | 11.9B | 14.4B | 13.2B | 12.0B | 12.0B | 11.0B | 11.6B |
| Cash & Short-term Investments | 2.33B | 1.94B | 1.69B | 1.43B | 3.23B | 2.30B | 1.17B | 1.87B | 2.40B | 2.79B | 2.75B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.32B | 2.93B | 2.43B | 1.91B | 2.64B | 5.03B | -185M | 2.14B | 1.57B | 1.17B | 1.48B |
| Capital Expenditure | 869M | 420M | 422M | 486M | 485M | 397M | 444M | 644M | 676M | 668M | 643M |
| Free Cash Flow | - | 1.01B | 937M | 1.02B | 1.84B | 866M | -979M | 1.49B | 893M | 504M | 835M |
| Ratios | |||||||||||
| ROE | 11.5% | 13.8% | 9.0% | 9.3% | 10.0% | 23.0% | -12.1% | -3.9% | -5.8% | 8.2% | 6.5% |
| ROA | 4.5% | 6.5% | 4.2% | 4.3% | 4.3% | 10.7% | -5.2% | -1.6% | -2.4% | 3.3% | 2.7% |
| Net Profit Margin | 5.9% | 9.3% | 6.0% | 6.0% | 6.1% | 19.3% | -9.0% | -2.6% | -3.9% | 5.0% | 4.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Koninklijke Philips NV dividends
- Dividend yield
- 1.22%
- Forward dividend
- 0.85 EUR
- Payout ratio
- 36.6%
- Ex-dividend date
- May 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 328M | 0.34 | 36.6% |
| 2024 | EUR 1.00M | 0.00 | - |
| 2023 | EUR 2.00M | 0.00 | - |
| 2022 | EUR 412M | 0.45 | - |
| 2021 | EUR 482M | 0.55 | 14.5% |
| 2020 | EUR 1.00M | 0.00 | 0.1% |
| 2019 | EUR 453M | 0.50 | 38.8% |
| 2018 | EUR 401M | 0.43 | 36.8% |
| 2017 | EUR 384M | 0.41 | 23.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30.2684:29.2684 on May 9, 2024.
Who owns Koninklijke Philips NV
- Insiders 18.98%
- Institutions 50.32%
- Public & others 30.70%
- Shares outstanding 978M
- Free float 977M
Koninklijke Philips NV company profile
- Company name
- Koninklijke Philips NV
- Ticker
- PHI1.F
- ISIN
- NL0000009538
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 63,909
- Fiscal year end
- December
- Address
- Philips Center, Amsterdam, Netherlands, 1077 WV
- Phone
- 31 20 597 7777
- Website
- philips.com
About Koninklijke Philips NV
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Koninklijke Philips NV management
10- Mr. Roy Willem Odilia JakobsPresident, CEO & Chairman of the Board of Management · born 1974
- Dr. Paulus A. Stoffels M.D., Ph.D.Independent Vice Chairman of Supervisory Board & Secretary · born 1962
- Ms. Charlotte HannemanExecutive VP, CFO & Member of Board of Management · born 1978
- Mr. Marnix J. van Ginneken Ph.D.Executive VP, Chief ESG & Legal Officer and Member of the Board of Management · born 1973
- Mr. Willem AppeloExecutive VP & COO · born 1964
- Ms. Laura MatzExecutive VP and Chief Innovation & Technology Officer
- Ms. Durga DoraisamyHead of Investor Relations
- Ms. Heidi SichienExecutive VP & Chief People Officer · born 1974
- Dr. Jan Kimpen M.D., Ph.D.Chief Medical Officer · born 1958
- Mr. Pim PreesmanCountry Leader/ Health Systems Leader Indonesia